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grafts is relatively recent. We sought to determine whether
there was a detectable difference in mortality rate, compli-
cation rate, and LOS in our patients and to examine the
durability of these benefits of EVAR during the mid-term
follow-up interval.
METHODS
The records of patients admitted to the hospital for
infrarenal aortic aneurysm repair during a consecutive 26-
month interval ending in December 2000 were reviewed.
In addition, the records of all subsequent admissions and
outpatient visits of these patients were examined. Patient
demographics, diagnoses, procedures, and LOS were
recorded in a database. LOS was counted beginning with
the day of the patient’s surgical abdominal aortic
aneurysm (AAA) procedure.
Patients were identified as high risk on the basis of car-
diopulmonary risk factors. The factors included unstable
angina, significant areas of myocardium at risk on the basis
of coronary angiography or radionuclide scan results, left
ventricular ejection fraction of less than 20%, recent con-
gestive heart failure, chronic obstructive pulmonary dis-
Endovascular repair of abdominal aortic aneurysms
(EVAR) has become widespread since the Food and Drug
Administration approval of devices for commercial use.
The patient demand for these devices is great because of
the perception that the procedure is less invasive and offers
quicker recovery than conventional open aneurysm
surgery (COS). The cost of these devices is high but has
been justified on the basis of decreased patient length of
stay (LOS), which results in an offsetting of cost savings.1-4
The long-term results of the procedure, however, are not
yet known because the entire experience with aortic endo-
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Purpose: Endovascular abdominal aortic aneurysm (AAA) repair is reported to result in less initial patient morbidity
and a shorter hospital length of stay (LOS) when compared with conventional AAA repair. We sought to examine the
durability of this result during the intermediate follow-up interval.
Methods: The records of all admissions for all patients who underwent AAA repair during a 26-month interval were
reviewed.
Results: Three hundred thirty-seven (337) patients underwent procedures to repair AAAs (163 open and 174 endovas-
cular). Endovascular procedures were performed with a variety of devices (Talent, 108; Ancure, 36; AneuRx, 26;
Zenith, 2; and Cordis, 2) and configurations (141 bifurcated and 33 aortomonoiliac). The mean follow-up period was
10.6 months (endovascular repair) and 12.3 months (open repair). LOS did not significantly vary by device (P = .24
to P = .92) or configuration (P = .24). The initial median LOS for procedures was significantly shorter (P = .009) for
endovascular repairs (5 days) than for open procedures (8 days). However, the patients who underwent endovascular
repair were more likely to be readmitted during the follow-up interval when compared with patients who underwent
open procedure. The readmission-free survival rate after AAA repair at 12 months was 95% for patients for open AAA
repair versus 71% for patients for endovascular repair (P < .001). If the total hospital days were compared, including
the initial and all subsequent AAA-related admissions, there was no significant difference for mean LOS for patients
who underwent endovascular versus open AAA procedures (11 days versus 13.6 days; P = .21). The patients for
endovascular AAA repair most commonly needed readmission for treatment of endoleak (n = 31), wound infection (n
= 12), and graft limb thrombosis (n = 9). Although women had similar LOS to men for endovascular repair (P = .44),
they had longer initial LOS for open AAA repair (15 versus 10 days; P = .03). After endovascular repair, women were
more likely than men to be readmitted by 12 months (51% versus 71% readmission-free survival rate; P = .03) and they
had longer LOS on readmission (13.2 versus 5.2 days; P = .006). No gender differences were identified for patients
after open AAA repair regarding readmission-free survival rate (P = .09) or LOS on readmission (P = .98).
Conclusion: Although initial LOS was shorter for the patients who underwent endovascular as compared with conven-
tional AAA repair, this advantage was lost during the follow-up interval because of frequent readmission for the treat-
ment of procedure-related complications, chiefly endoleak. These readmissions frequently involved the performance of
additional invasive procedures. Gender differences existed regarding LOS and the likelihood of complications after
open and endovascular AAA repair. (J Vasc Surg 2002;35:222-8.)
ease that required home oxygen therapy, or forced expira-
tory flow of less than 20% of predicted.
All the COS and EVAR procedures were performed
with general anesthesia. The patients underwent EVAR as
participants in Food and Drug Administration–approved
device trials or with commercially available devices. Follow-
up examination for patients for EVAR consisted of con-
trast-enhanced computed tomographic (CT) scanning at
30 days, 6 months, and annually after the initial procedure.
Additional studies were obtained if clinically indicated. The
clinical device trials were approved by and complied with
the University’s Committee on Studies Involving Human
Beings. The clinical trials included both low-risk (patients
with conditions considered fit for COS and for EVAR) and
high-risk (patients with conditions considered fit for EVAR
but not for COS) protocols. None of these trials specified
LOS restrictions. Statistical analysis was performed with
StatView statistical software (SAS Institute, Inc, Cary, NC)
for Student t test and life table.
RESULTS
The patient demographics are shown in Table I.
During the 26-month study interval, 337 patients under-
went AAA repair at a single hospital. Of these, 163 proce-
dures (124 male and 39 female patients) were performed
with COS and 174 procedures (159 male and 15 female
patients) were performed with EVAR. Of the patients for
EVAR, 67 (39%) were considered to be at too high a risk
for COS because of severe comorbidity. The endovascular
devices used and the device configurations (bifurcated ver-
sus aortomonoiliac) are shown in Table II. The mean fol-
low-up period was 10.6 months for patients for EVAR and
12.3 months for patients for COS.
In the perioperative period, there were seven deaths in
the COS group (4.4%) and seven deaths in the EVAR
group (4.0%; P = .90). Of the EVAR deaths, none were in
the low-risk group and seven (9%) were in the high-risk
EVAR group (P < .001). When compared with the
patients for COS, the patients at low risk for EVAR had a
lower mortality rate (P = .04). The mortality rate of the
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patients at high risk for EVAR did not differ significantly
from that of the patients for COS (P = .06). The causes of
death and LOS for these patients are shown in Table III.
LOS (Table IV) was shorter at the initial admission for
aneurysm repair when the procedure was performed with
EVAR as compared with COS (P = .009). Women had a
longer average LOS than did men for open procedures 
(P < .03) but not for EVAR (P = .44).
During the 26-month follow-up interval, readmission
to the hospital for the treatment of complications of the
initial AAA repair procedure was necessary for 16 patients
for COS (9.8%) and for 44 patients for EVAR (25%). The
AAA-related reasons for readmission are shown in Table V.
Readmission for reasons unrelated to the AAA procedure
were noted for seven patients for EVAR and for three
patients for COS. These latter readmissions were for can-
cer therapy (n = 3), popliteal aneurysms (n = 2), colitis 
(n = 1), heart transplant (n = 1), carotid endarterectomy
(n = 1), peripheral bypass grafting (n = 1), and hemopty-
sis (n = 1). No differences in rates for specific complica-
tions were found for gender, risk group (high or low),
device type, or configuration. No complications were
attributed to our routine use of general anesthesia. No
patients for EVAR needed conversion to COS for treat-
Table III. Causes of death and length of stay for
endovascular abdominal aortic aneurysm repair*
Patient Cause of death LOS (days)
1 Sepsis/MSOF 38
2 Cardiac 2
3 Pulmonary 107
4 Pulmonary 35
5 ESLD 26
6 Cardiac 27
7 Cardiac 43
*All seven deaths were in the high-risk group of endovascular abdominal
aortic aneurysm repair.
LOS, Length of stay; MSOF, multiple system organ failure; ESLD, end-stage
liver disease.
Table II. Devices and configurations used in 174
endovascular abdominal aortic aneurysm repair proce-
dures
No. of procedures
Device*
Talent 108
Ancure 36
AneuRx 26
Zenith 2
Cordis 2
Configuration
Bifurcated 141
Aortomonoiliac 33
*Talent, Medtronic AVE, Sunrise, Fla; Ancure, Guidant, Menlo Park, Calif;
AneuRx, Medtronic, Minneapolis, Minn; Zenith, Cook, Bloomington, Ind;
Cordis, Johnson & Johnson, Warren, NJ.
Table I. Patient characteristics (n = 337)
Characteristic EVAR COS P value
Mean age (years) 77.3 74.0 <.001
Male 159 124 <.001
Female 15 39 <.001
CAD 81 (47%) 47 (29%) <.001
COPD 35 (20%) 33 (20%) .98
CRI (Cr > 1.5 mg/dL) 26 (15%) 20 (12%) .48
Hypertension 113 (65%) 108 (66%) .8
Patients for endovascular abdominal aortic aneurysm repair were signifi-
cantly older, with more coronary artery disease, than were patients for con-
ventional open surgery. There was significantly lower proportion of female
patients accepted for endovascular abdominal aortic aneurysm repair than
for conventional open surgery.
EVAR, Endovascular abdominal aortic aneurysm repair; COS, conventional
open surgery; CAD, coronary artery disease; COPD, chronic obstructive
pulmonary disease; CRI, chronic renal insufficiency; Cr, creatinine level.
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ment of complications. Multiple readmissions were
needed for only two patients for COS (1%) but were com-
mon for patients for EVAR (11 patients readmitted twice,
six readmitted three times, and two readmitted four
times). This produced a total of 19 COS readmissions and
63 EVAR readmissions for treatment of complications
related to the initial AAA procedure.
The mean LOS for patients who were readmitted
(Table IV) was 8.2 days after COS and 6.8 days after
EVAR. Women had a longer average LOS than did men
when readmitted for complications of EVAR (P = .006).
No gender differences were found for readmission mean
LOS after COS (P = .98).
The total LOS for the study interval, including the
original AAA repair admission and all subsequent readmis-
sion hospital days necessary for treatment of AAA-related
complications, was calculated (Table IV). For patients for
COS, the average total LOS was 13.6 days as compared
with 11.0 days for patients for EVAR (P = .21). The total
LOS after COS was significantly longer for women than
for men (P = .004).
The readmission-free survival rate after AAA repair was
calculated with life table (Fig). The readmission-free survival
rate at 12 months was greater for patients who underwent
treatment with COS (95%) than for patients who underwent
treatment with EVAR (71%; P < .001). Gender differences
that showed better readmission-free survival rates at 12
months for men than for women (71% versus 52%; P = .03)
were found after EVAR but not after COS (P = .09).
Table IV. Length of stay
Patient group Mean Median Range Comparison P value
Initial admission length of stay
COS 11.3 8 5 – 95 COS vs EVAR .009
Male 10.2 7 5 – 95 COS male vs female .03
Female 15 9 5 – 58 EVAR high risk vs low risk <.001
EVAR 7.4 5 2 – 95 EVAR male vs female .44
Male 8.2 4 2 – 95
Female 5.6 5 2 – 11
High risk 11.8 7.5 2 – 95
Low risk 5.5 4 2 – 46
Readmission length of stay
COS 8.2 6 1 – 24 COS vs EVAR .98
Male 8.2 7 1 – 24 EVAR male vs female .006
Female 8.1 9.5 1 – 12 EVAR high risk vs low risk .2
EVAR 6.8 3 1 – 66
Male 5.2 3 1 – 33
Female 13.2 7 1 – 66
High risk 5.1 3 1 – 16
Low risk 8.1 3 1 – 66
Total AAA-related length of stay
COS 13.6 8.5 5 – 95 COS vs EVAR .21
Male 11.2 8 5 – 91 EVAR high risk vs low risk .02
Female 17.8 10 5 – 95 COS vs EVAR high risk .65
EVAR 11 6 2 – 95 COS vs EVAR low risk .006
Male 10.3 6 2 – 95
Female 16.8 8 2 – 95
High risk 14.6 9 5 – 95
Low risk 8.7 4 2 – 95
COS, Conventional open repair; EVAR, endovascular abdominal aortic aneurysm repair; AAA, abdominal aortic aneurysm.
Table V. Indications for readmission to hospital during
26 months after AAA repair*
Indications No. of patients
After COS (19 readmissions for 16 patients)
Gastrointestinal 6
Pulmonary 4
Wound infection 2
Ventral hernia 2
Peripheral vascular 1
Renal failure 1
Urinary tract infection 1
Sepsis 1
Endocrine 1
After EVAR (63 readmissions for 44 patients)
Endoleak 31
Wound infection 12
Endolimb failure 9
Renal failure 3
Abdominal pain 3
Pulmonary 2
Cardiac 2
Fever 2
*Readmissions for reasons unrelated to abdominal aortic aneurysm repair
(n = 10) are not included. No differences were identified for specific com-
plications according to gender, device type or manufacturer, or risk group
(high vs low risk endovascular abdominal aortic aneurysm repair).
COS, Conventional open repair; EVAR, endovascular abdominal aortic
aneurysm repair.
Subgroup analysis of patients for EVAR with risk strati-
fication (high risk versus low risk; Table IV), device config-
uration, and manufacturer was performed for the
determination of differences in LOS and readmission-free
survival rates. The mean total LOS for patients at high risk
for EVAR was 14.6 days and for patients at low risk was 8.7
days (P = .02). In comparison with COS, there was no sig-
nificant difference in total LOS for patients at high risk for
EVAR (P = .65), but patients at low risk for EVAR had a
shorter mean total LOS (P = .006). Patients at high risk for
EVAR had a longer mean LOS on initial admissions than did
patients at low risk for EVAR (P < .001). The readmission
mean LOS was not significantly different for patients at high
risk and low risk for EVAR (P = .2). The readmission-free
survival rate was not significantly different between patients
at high and low risk for EVAR (P = .96). The COS read-
mission-free survival rate was significantly better when com-
pared with patients at high risk 
(P < .001) or low risk (P < .001) for EVAR. No differences
between devices or configurations were noted in initial LOS
or readmission-free survival rate (Table VI). For the deter-
mination of the effect of operator and institutional experi-
ence on LOS and complications, an analysis comparing the
first 87 patients for EVAR with the last 87 patients for EVAR
was performed. No significant differences in initial or total
LOS (P = .14) or readmission-free survival rate were noted.
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DISCUSSION
We found that, at the time of admission for AAA
repair, EVAR results in decreased LOS when compared
with COS. Decreased initial LOS with EVAR has been
described by virtually all authors who compare EVAR and
COS.5-8 EVAR provides less physiologic insult than does
COS,9-11 which allows for a speedier discharge from the
hospital. With subgroup analysis, however, this benefit was
only seen in our patients at low risk for EVAR. The
patients at high risk for EVAR had equivalent LOS to the
patients for COS but were not medically fit candidates for
COS. Although the availability of EVAR allowed us to
treat patients who otherwise could not have undergone
any intervention for their aneurysms, it did not provide a
LOS benefit at their initial admissions to the hospital.
We also noted that readmission to the hospital after
EVAR was common, occurring in 25% of the patients,
many of who needed multiple readmissions. This rate is
similar to findings of other reported series.12-15 When total
hospital days were examined, including both the original
admissions for AAA repair and all subsequent readmissions
for treatment of AAA-related complications, the LOS ben-
efit of EVAR was lost. Only for the low risk subgroup of
patients for EVAR did the decreased total LOS benefit
continue to be significant during the follow-up interval.
Although readmission after COS was uncommon,
these readmissions were usually in the immediate 4 to 6
week postoperative period, and late complications of COS
were rare (two ventral hernias). In contrast, readmission
after EVAR was noted throughout the follow-up interval,
which indicated that the patients remained at risk for
AAA-related complications for the long term after the
EVAR procedure. Neither the high risk or the low risk
EVAR subgroup showed readmission-free survival rates
that were comparable with COS. Readmission seemed to
be a function of the EVAR procedure itself rather than
patient comorbidity.
The most common reason for readmission after EVAR
was endoleak. A full discussion of our experience with
endoleak has been detailed elsewhere.16,17 In this series,
no patients needed conversion to COS for the treatment
Readmission-free survival rate after abdominal aortic aneurysm (AAA) repair. Readmission-free survival rate at 12 months was 95% for
conventional open aneurysm surgery (COS) versus 71% for endovascular AAA repair (EVAR; P < .001). Patients for EVAR continued
to be at risk for readmission in later follow-up period, whereas patients for COS were unlikely to be readmitted for AAA-related reasons
beyond first month after AAA repair.
Table VI. Length of stay and readmission-free survival
rate by device type and configuration
P value
Length of stay (initial admission)
AneuRX vs Ancure .43
Ancure vs Talent .08
AneuRX vs Talent .59
Bifurcated vs aortomonoiliac .11
Readmission-free survival rate
AneuRX vs Ancure .28
Ancure vs Talent .92
AneuRX vs Talent .24
Bifurcated vs aortomonoiliac .24
of endoleak. However, multiple readmissions for the treat-
ment of endoleak with catheter-based therapies were often
necessary.16-20 Disturbingly, some patients without evi-
dence of endoleak on early follow-up CT scan results
showed endoleaks in the later follow-up interval.
The estimates of the prevalence of endoleak after
EVAR are quite variable and range from 10% to 50%.20-29
Although many endoleaks resolve spontaneously, many do
not.26,29-31 Some investigators have chosen to observe
these leaks and treat only expanding aneurysm sacs that
harbor endoleaks, but it has been established that even
branch endoleaks (type II) can transmit systemic pressure
to the aneurysm sac, leaving the patient unprotected from
AAA rupture.19 It is incumbent on the treating physician
to find and treat these leaks to provide the patient with an
adequate repair. This process requires repeated imaging
evaluations, usually with ultrasound or CT scanning, and
intervention for persistent endoleaks.14
The phenomenon of endotension, whereby aneurysms
are noted to enlarge or not to shrink after EVAR, despite
the absence of a demonstrable endoleak, is poorly under-
stood and could represent an additional population of
patients who will need readmission for remediation.32-34
The need for long-term follow-up examination of these
patients is essential.35 Lack of willingness to keep follow-
up appointments and to undergo subsequent interven-
tions should be considered a relative contraindication to
EVAR.
We and others25,30,36,37 have also described failures of
endovascular graft limbs. This was the third most common
reason for readmission after EVAR. Like endoleak, this
complication could occur early or late in the follow-up
period. It is more prevalent in unsupported graft limbs,
which prompts some investigators to recommend routine
stenting of all unsupported graft limbs to improve their
durability. The phenomenon has been noted in fully sup-
ported grafts as well, however. It is postulated that, over
time, conformational changes in the excluded AAA sac
(shrinkage) lead to the introduction of kinks in the
endolimbs. Sac shrinkage is a desirable result of successful
EVAR but places patients at risk for this later complica-
tion.38,39 These conformational changes have also led to
separation of modular graft components, which leads to
delayed endoleak and AAA rupture.40
We noted that women were more likely to be read-
mitted after EVAR than were their male counterparts and,
when readmitted, stayed longer. Women also were found
to have a longer LOS after COS. Gender differences have
been noted previously regarding suitability for EVAR,41
which indicates that female patients are less likely to qual-
ify for the procedure than are male patients. In this study,
we also noted a significantly higher proportion of women
in our COS patient population than in our EVAR popula-
tion (P < .001). This difference is not only the result of the
smaller size of female access vessels (iliofemoral) but is also
related to the more frequently unsuitable aortic neck
anatomy found in female patients with AAA. Women are
more likely to have short, wide, and angulated aortic
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necks, which excludes them from candidacy for EVAR.
None of these anatomic features, however, contributed to
the increased LOS noted in this report and the explana-
tion of these findings remains unclear.
Other complications might be anticipated with longer
follow-up periods. Progressive dilatation of aneurysm
necks after EVAR has been described.42,43 Whether this
will lead to late attachment site failures is as yet not
known. Devices have shown failure of metal struts and
fabric erosions and migration, which results in a loss of seal
and the failure of the device to protect the patient from
the risk of aneurysm rupture.40,44,45 All of these limita-
tions of EVAR suggest that a cautious approach to the rec-
ommendation of the procedure and careful monitoring of
patients after EVAR is appropriate while the technology
continues to develop solutions to these problems.
Cost is one of the greatest limitations of EVAR. It has
been hoped that the increased costs associated with these
devices will be offset by decreases in morbidity and hospi-
tal LOS.1-4 Our findings would suggest that although the
initial LOS is substantially shorter for EVAR than it is for
COS (although not for patients at high risk), during the
follow-up interval this cost savings is likely to be negated.
In many cases, EVAR cannot be considered to be a defin-
itive procedure in and of itself, independent of the
required remedial admissions and adjunctive procedures.
This inflates the overall cost of the approach. It is hoped
that with refinement of the technology, this need will
diminish. Even those patients who do not need subse-
quent supplemental intervention after EVAR continue to
need periodic imaging, which represents an incremental
cost disadvantage when compared with COS.
Patient satisfaction after EVAR is controversial.
Although patients enthusiastically embrace the procedure
before surgery, it appears that their resulting satisfaction
may be equal to or less than that of their COS counter-
parts after the passage of time. This result is believed to be
caused by dissatisfaction with the need for frequent AAA-
related tests and procedures after EVAR, which are
uncommon for COS.46 Adjustment of patient expecta-
tions and education regarding the need for continued fol-
low-up examination and the likelihood of remedial
procedures after EVAR are essential preoperative prepara-
tion for this procedure.
In summary, EVAR has allowed us to decrease the
physiologic stress of AAA repair, which has permitted us to
safely treat patients who would not otherwise be eligible
for repair of aneurysms. This is reflected in a decreased ini-
tial LOS overall for the EVAR procedure when compared
with COS. The technology, however, is still in its infancy
and as yet cannot serve as a “stand alone” procedure, as
reflected in the frequent need for readmission of these
patients for remedial procedures. Longer follow-up stud-
ies must be performed to determine the ultimate differ-
ences in cost and morbidity between the two methods of
AAA repair. At present, a cautious approach to the recom-
mendation of EVAR must be made. Frequent imaging is
necessary to monitor the adequacy of the endovascular
repair as a protection from aneurysm rupture. These latter
challenges inflate the cost of this approach. Patient educa-
tion regarding appropriate expectations and the need for
frequent follow-up tests and procedures is essential to
obtain successful and satisfying long-term results.
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Dr Matthew J. Dougherty (Philadelphia, Pa). One clarifica-
tion: the length of stay data you presented, is that postoperative
length of stay or does that include preoperative days, which might
certainly have skewed your series, especially in the high-risk group?
Dr Jeffrey P. Carpenter. No, this starts from the admission for
the aneurysm procedure. So, our patients, I am sure, like yours,
cannot have pre-days anymore. We have AM admission on the day
of endovascular repair for almost all these patients.
Dr Dougherty. Sure, but a lot of these patients may have been
in-patients for other reasons related to their comorbidities and
you may have been consulted and proceeded with repair during
the same admission, which could skew things.
The second question is, your group has had a more aggressive
than average posture with regard to endoleaks; do you think some
of the late length-of-stay days may just be related to the fact that
you are treating a lot of things that perhaps some of us would not?
Dr Carpenter. Well, I think that it has become clear over the
last year and a half or 2 years that even type 2 endoleaks can trans-
mit systemic pressure to the aneurysm sac. And on the basis of a
manuscript we presented here last year, where we actually meas-
ured the sac pressures, we have in fact been very aggressive about
going after endoleaks.
We do not treat any endoleaks until we see them on the 30-
day CAT scan, so nothing happens immediately. But at 30 days, if
the patient has a persistent endoleak, that will prompt at least an
outpatient arteriogram. And if they have, at that time, an endovas-
cular procedure, a translumbar embolization or angiographic
intraluminal embolization, that will be readmission at that time.
Dr Takao Ohki (Bronx, NY). I think there is some overlap
with the previous question. My question is more towards the sec-
ond admission where you fixed, I guess, an endoleak or a limb
thrombosis, the number one or three cause of readmission. The
length of stay for that was 6.8 days. I am very puzzled with why
coil embolization, where in your group you do it from the
translumbar, which I think is a great way to do to, or limb throm-
bosis, which is usually managed by a fem-fem or thrombolysis,
would take a week of length of stay? And that would change the
entire taste or conclusion of your paper. I am just puzzled with
the long length of stay, not just for the primary operation but for
the secondary operation also.
Dr Carpenter. Yes, I understand your concern about that. Many
of our endoleak patients had to be readmitted multiple times. We
would fix an endoleak, and then they would develop a new one sev-
eral months later. Originally, we were using coil embolizations of
the IMA inserted through the SMA, and later we determined that
a lot of these, which initially were successful, would break down
and these patients would have to be readmitted. So, there are mul-
tiple readmissions that are short readmissions.
Now, the average readmission length of stay, as you said, is
longer, and I think that is the effect of a skewed curve. Some
patients came and stayed forever. Many patients had short read-
mission length of stays. The median readmission length of stay is
much shorter.
Dr Ohki. And just one final comment. I know Richard Baum
treats patients with no leak and stable aneurysm or non-shrinking
aneurysm with the translumbar technique and that does increase
the number of readmissions as compared to others, who usually
would not treat such patients.
Dr Carpenter. In this study, none of the endotension readmis-
sion patients are included. This study interval ended before we
adopted the practice of studying our endotension patients.
Dr Maciej L. Dryjski (Buffalo, NY). I have two questions.
How did you define high-risk patients? And what are your crite-
ria for operating on these patients? What is the size of aneurysm
you think should be operated on in these high-risk patients?
Dr Carpenter. Most of the study patients were in the context of
phase I, II, or III clinical trials, so a high-risk patient was defined
by the manufacturer. High-risk patients really are high risk, usually
for unreconstructible coronary disease, very low ejection fractions,
severe COPD, or home oxygen dependence. It is specific to each
trial, but there are very clearcut and objective guidelines for the
definition of a high-risk patient for each of those trials.
Dr Dryjski. And what size of aneurysm would you operate on
these patients?
Dr Carpenter. I believe the minimum aneurysm was 4.5 cm.
Most patients had aneurysms greater than 5 cm.
Dr John W. Hallett, Jr (Rochester, Minn). In the past several
years, all of us who have done stent grafts have been impressed
with the expediency of the procedure, and today you make us
look frankly at the durability of the benefits. One of your recom-
mendations was patient education. You have had this data now for
over 6 months. How much of this have you shared with your
patients in your informed consent?
Dr Carpenter. I think it is very important to have frank dis-
cussions with your patients, and my office hours have taken a lot
longer since we examined these data. I would say that I spend
most of my office hour time now persuading my patients who can
undergo conventional open surgery safely to undergo that proce-
dure. Many of you, I am sure, have patients come to your office
with web sites printed out. They will even tell you what stent graft
they would like you to use. For them, the decision is not whether
they are having a stent graft or not. It takes a lot of talking, but 
I think patients who are educated about the procedure will make
a decision to have an open repair if they are medically fit.
Dr Jeffrey L. Ballard (Loma Linda, Calif). I did not hear you
comment on aortic exposure in your open cases. If these were all
retroperitoneal exposures, do you think that your length-of-stay
data would be even lower for your open group, and would this
then magnify the cost difference between the two approaches?
Dr Carpenter. I love retroperitoneal exposure. I have not
examined it, but I would suspect a third are done by a retroperi-
toneal incision. We have not really seen a length-of-stay difference
between the two approaches, although I always feel that there is
less pulmonary morbidity and I can feed the patient sooner. But
perhaps you are right that that would make it even more dra-
matic.
DISCUSSION
